Sanai Health Industry Group Company Limited provided group earnings guidance for the year ended December 31, 2023. For the period, the company expected that the Group will record a significant decrease in revenue and gross profit margin, which resulted in the substantial decrease in net profit attributable to the owner of the Company of not more than 40% as compared with that for the corresponding period of 2022. The significant decrease in revenue and gross profit margin was mainly attributable to the decrease in sales volume of self-manufactured pharmaceutical products and substantial increase in the general costs of traditional Chinese herb materials in the PRC during the Reporting Period.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.028 HKD | +7.69% | +7.69% | -56.25% |
1st Jan change | Capi. | |
---|---|---|
-56.25% | 13.7M | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- 1889 Stock
- News Sanai Health Industry Group Company Limited
- Sanai Health Industry Group Company Limited Provides Group Earnings Guidance for the Year Ended December 31, 2023